SAN DIEGO--(BUSINESS WIRE)--Hollis-Eden Pharmaceuticals, Inc. (NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous adrenal steroid hormones, announced that it has commenced a Phase I/II open label dose ranging clinical trial with its investigational oral drug candidate TRIOLEX™ (HE3286) in patients diagnosed with rheumatoid arthritis (RA) and receiving a stable dose of methotrexate, the current standard of care in RA.
